Hesai Secures New Lidar Design Win with a Top 5 Chinese NEV Automaker, Entering Mass Production Phase this Year

2025-03-15 Hesai Technology HaiPress

PALO ALTO,Calif.,March 13,2025 -- Hesai Technology,a global leader in lidar R&D and manufacturing,has secured a new design win with a top 5 NEV automaker in China. This automaker,part of a major global automotive group,will soon commence mass production of its high-end smart EV models equipped with Hesai's ATX lidar as standard. The ATX's advanced features will significantly enhance the vehicles' intelligent driving systems.

The lidar market is experiencing rapid growth,with automotive lidar installations surpassing 1.5 million units in 2024,doubling the previous year's figure. Gasgoo Automotive Research Institute's data reveals a 29% penetration rate of lidar in China's EV market priced above $20,000 as of December 2024,highlighting its role as a crucial safety feature.

Hesai's ATX,powered by its cutting-edge fourth-generation technology platform,features a redesigned opto-mechanical structure and upgraded laser transceiver modules. This achieves a compact form factor without compromising performance. With mass production underway and an annual capacity of 2 million units planned,Hesai is well-prepared to meet the growing demand from automakers in 2025.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

©copyright 2009-2020 Singapore Info Map